Management ChangeJul 16, 2026, 04:37 PM
Gyre Therapeutics Appoints Three New Board Directors
AI Summary
Gyre Therapeutics, Inc. announced the appointment of three new members to its Board of Directors, effective August 1, 2026. Yue Xiong, Ph.D., Maxwell Kirkby, and Claire Weston, Ph.D. will join the board, with Mr. Kirkby also appointed to the Compensation Committee and Dr. Weston to the Audit Committee. The company stated these appointments will expand its scientific, clinical development, and cross-border biopharmaceutical operating expertise.
Key Highlights
- Yue Xiong, Ph.D., Maxwell Kirkby, and Claire Weston, Ph.D. appointed as new directors, effective August 1, 2026.
- Dr. Xiong appointed as a Class I director, Mr. Kirkby as a Class II director, and Dr. Weston as a Class III director.
- Mr. Kirkby will serve on the Compensation Committee of the Board.
- Dr. Weston will serve on the Audit Committee of the Board.
- Mr. Kirkby and Dr. Weston will each receive an initial grant of 40,000 stock options.
- Mr. Kirkby and Dr. Weston will receive cash compensation per the non-employee director policy.
- Dr. Xiong will receive no additional compensation for his board service as he is already CSO.
Price Impact
More from GYRE